1.63 POLO, TITAN, & from ASCO: FDA Approval, Surrogate Endpoints, and Patient Experience

This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO.

POLO: doi.org/10.1056/NEJMoa1903387
TITAN: doi.org/10.1056/NEJMoa1903307

Back us on Patreon! www.patreon.com/plenarysession